NEUROENDOCRINE TUMOR TREATMENT MARKET ANALYSIS

Neuroendocrine Tumor Treatment Market, By Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Global Neuroendocrine Tumor Treatment Market: Key Developments

On April 2023, researchers in Madrid from Cambridge University announced a global collaboration with researchers at the Spanish National Cancer Research Center (CNIO) for the genomic study of rare neuroendocrine tumors known as pheochromocytomas and paragangliomas (PPGLs) from immunotherapy. The aim of the collaboration is to provide patients with early diagnosis of the primary tumor and stop the growth of cancer cell.
On November 2022, the government of the U.S., on the occasion of World Neuroendocrine Cancer Awareness Day, conducted an awareness campaign on therapeutic options for well-differentiated NETs (neuroendocrine tumors) in partnership with City of Hope Medical Center, based in California.
In September 2022, Eli Lilly and Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted approval to Retevmo (selpercatinib, 40 mg and 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors. In the LIBRETTO-001 trial, selpercatinib demonstrated clinically durable responses across a variety of tumor types in patients with RET-driven cancers, including pancreatic, colon, and other cancers.